What changed: Prostate cancer
Every dated change on the records linked to Prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
July 2026 · 1
June 2026 · 1
Q2 2026 · 1
March 2026 · 1
2026 · 3
- 2026ApprovalCapivasertibCapivasertib approved in US
PTEN-deficient metastatic prostate cancer with abiraterone
- 2026ApprovalPiflufolastat F-18 / Pylarify TruVuPiflufolastat F-18 / Pylarify TruVu approved in US
Pylarify TruVu formulation
- 2026MilestonePSMAdditionPluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient disease
A milestone in how this cancer is treated.
August 2025 · 1
2025 · 7
- 2025ApprovalArteraAI ProstateArteraAI Prostate approved in US
Localised prostate cancer risk stratification and ADT benefit prediction
- 2025ApprovalIlluccix (kit for Ga-68 gozetotide)Illuccix (kit for Ga-68 gozetotide) approved in US
Gozellix kit; selection of patients for PSMA-targeted radioligand therapy
- 2025Trial resultCAPItello-281CAPItello-281 reported
rPFS significantly improved (HR reported at presentation); approved 2026.
- 2025Trial resultECLIPSEECLIPSE reported
rPFS significantly improved.
- 2025Trial resultPSMAdditionPSMAddition reported
rPFS HR 0.
- 2025MilestoneArteraAI ProstateArteraAI Prostate: first predictive AI pathology test
A milestone in how this cancer is treated.
- 2025MilestonePSMAforePluvicto pre-chemotherapy (PSMAfore); ArteraAI Prostate FDA-authorised; PSMAddition positive; ECLIPSE positive; masofaniten discontinued
A milestone in how this cancer is treated.
2024 · 3
2023 · 6
- 2023ApprovalFlotufolastat F-18Flotufolastat F-18 approved in US
PSMA PET in prostate cancer
- 2023ApprovalPiflufolastat F-18 / Pylarify TruVuPiflufolastat F-18 / Pylarify TruVu approved in EU
EU brand Pylclari (Curium)
- 2023Trial resultEMBARKEMBARK reported
MFS HR 0.
- 2023Trial resultPSMAforePSMAfore reported
rPFS HR 0.
- 2023Trial resultTALAPRO-2TALAPRO-2 reported
rPFS HR 0.
- 2023MilestoneTALAPRO-2PARP + ARPI combinations approved (TALAPRO-2, PROpel, MAGNITUDE); EMBARK for biochemical recurrence
A milestone in how this cancer is treated.
2022 · 9
- 2022ApprovalLocametz (kit for Ga-68 gozetotide)Locametz (kit for Ga-68 gozetotide) approved in EU
PSMA PET in prostate cancer
- 2022ApprovalLocametz (kit for Ga-68 gozetotide)Locametz (kit for Ga-68 gozetotide) approved in US
PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy
- 2022ApprovalRezvilutamideRezvilutamide approved in CN
High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy
- 2022Trial resultARASENSARASENS reported
OS HR 0.
- 2022Trial resultGÖTEBORG-2 (MRI-based prostate cancer screening)GÖTEBORG-2 (MRI-based prostate cancer screening) reported
Clinically insignificant cancer 0.
- 2022Trial resultMAGNITUDEMAGNITUDE reported
BRCA cohort rPFS HR 0.
- 2022Trial resultPROpelPROpel reported
rPFS HR 0.
- 2022MilestoneLutetium-177 vipivotide tetraxetanPluvicto approved
A milestone in how this cancer is treated.
- 2022MilestoneLutetium-177 vipivotide tetraxetanPluvicto approved; ARASENS establishes triplet therapy
A milestone in how this cancer is treated.
May 2021 · 1
2021 · 9
- 2021ApprovalIlluccix (kit for Ga-68 gozetotide)Illuccix (kit for Ga-68 gozetotide) approved in Australia
PSMA PET imaging in prostate cancer
- 2021ApprovalIlluccix (kit for Ga-68 gozetotide)Illuccix (kit for Ga-68 gozetotide) approved in US
PSMA PET imaging in prostate cancer (initial staging with suspected metastasis; suspected recurrence)
- 2021ApprovalPaige Prostate DetectPaige Prostate Detect approved in US
Aid to pathologists in detecting areas suspicious for cancer on prostate needle biopsy slides (De Novo)
- 2021ApprovalPiflufolastat F-18 / Pylarify TruVuPiflufolastat F-18 / Pylarify TruVu approved in US
PSMA PET imaging in prostate cancer
- 2021Trial resultPEACE-1PEACE-1 reported
OS HR 0.
- 2021Trial resultPOP-RTPOP-RT reported
5-year biochemical failure-free survival 95% (whole pelvis) vs 81.
- 2021Trial resultTheraP (ANZUP 1603)TheraP (ANZUP 1603) reported
PSA50 66% vs 37%; OS HR 0.
- 2021Trial resultVISIONVISION reported
OS HR 0.
- 2021MilestoneVISIONVISION: 177Lu-PSMA-617 improves survival; TheraP beats cabazitaxel on response
A milestone in how this cancer is treated.
2020 · 7
- 2020ApprovalBRACAnalysis CDxBRACAnalysis CDx approved in US
Olaparib in germline BRCA-mutated metastatic castration-resistant prostate cancer
- 2020ApprovalGallium-68 gozetotide (PSMA-11)Gallium-68 gozetotide (PSMA-11) approved in US
PSMA PET (UCLA/UCSF NDA); kits 2021-2022
- 2020ApprovalRelugolixRelugolix approved in US
Advanced prostate cancer
- 2020Trial resultPROfoundPROfound reported
rPFS HR 0.
- 2020Trial resultproPSMAproPSMA reported
Accuracy 92% vs 65%.
- 2020MilestonePSMA PETPSMA PET approved; olaparib in HRR-mutant mCRPC
A milestone in how this cancer is treated.
- 2020MilestoneGallium-68 gozetotide (PSMA-11)PSMA PET approved; PROfound approves olaparib for HRR-mutant mCRPC
A milestone in how this cancer is treated.
2019 · 5
- 2019ApprovalPaige Prostate DetectPaige Prostate Detect approved in EU
CE mark
- 2019Trial resultARCHESARCHES reported
rPFS HR 0.
- 2019Trial resultHORRADHORRAD reported
Median overall survival 45 vs 43 months (hazard ratio 0.
- 2019Trial resultHYPO-RT-PCHYPO-RT-PC reported
5-year failure-free survival 84% in both arms, non-inferior.
- 2019Trial resultSABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancerSABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer reported
5-year OS 42.
2018 · 2
2017 · 4
- 2017ApprovalPadeliporfinPadeliporfin approved in EU
Unilateral, low-risk, previously untreated prostate adenocarcinoma in men with life expectancy of at least 10 years (Tookad VTP)
- 2017Trial resultLATITUDELATITUDE reported
OS HR 0.
- 2017Trial resultRTOG 9601RTOG 9601 reported
12-year overall survival 76.
- 2017MilestoneLATITUDELATITUDE and STAMPEDE: abiraterone in mHSPC
A milestone in how this cancer is treated.
2016 · 5
- 2016ApprovalFluciclovine F-18Fluciclovine F-18 approved in US
PET imaging in men with suspected prostate cancer recurrence based on elevated PSA
- 2016Trial resultCHHiPCHHiP reported
5-year biochemical or clinical failure-free survival 90.
- 2016Trial resultProtecTProtecT reported
15-year prostate-cancer mortality 3.
- 2016Trial resultSTAMPEDESTAMPEDE reported
Abiraterone + ADT: OS HR 0.
- 2016MilestoneProtecTProtecT validates active surveillance
A milestone in how this cancer is treated.